AZD7442 monoclonal antibodies are efficacious in the prevention of COVID-19
1. Compared to placebo, intramuscular AZD7442 had a relative risk reduction of 76.7% for symptomatic incident coronavirus disease 2019 (COVID-19)....
Accelerated approval drugs incur significant fee-for-service Medicare costs
1. Medicare beneficiaries used 36 accelerated approved drugs across 55 indications, totaling $1.2 billion in Medicare fee-for-service spending in 2019....
Tranexamic acid decreases postoperative bleeding in non-cardiac surgery patients
1. Compared to placebo, tranexamic acid (TXA) use in noncardiac surgery patients reduced the risk of bleeding 30 days postoperatively...